Private Equity

Blackstone builds on Pfizer ties with $1.5bn obesity drug investment

Reported by Alternatives Watch

Nov 12, 2026· 1 min read

Blackstone commits up to $1.5 billion toward Pfizer’s monthly GLP-1 obesity drug berobenatide, bringing its Pfizer funding deals to nearly $2.4 billion.

Read Full Article

Want more insights?

An AlphaMaven membership unlocks every executive summary, the full screener, and 124K+ alternative investment headlines — from $99/mo.

Start researching — $99/mo

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Alternatives Watch Blackstone builds on Pfizer ties with $1.5bn obesity drug investment

ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.

Want more insights?

Sources

Not a member yet?

The Alternative InvestmentIntelligence Platform

The Alternative Investment
Intelligence Platform